Adverse Effects Associated with SBRT in Patients With HCC

Survival results from the phase 3 CheckMate –9DW trial support the application for the combination therapy in treating hepatocellular carcinoma.

Govindarajan Narayanan, MD, speaks to the potential time-saving advantages of using the Epione robot for microwave ablation, cryoablation, and other surgical strategies in patients with liver cancer and other tumors.

Investigators of the HEPATORCH trial will present additional data on toripalimab plus bevacizumab in this population at a future academic conference.

The 5-year follow-up results from CheckMate 040 showed consistent responses with nivolumab/ipilimumab in advanced hepatocellular carcinoma.

The agency issues a complete response letter for the combination due to deficiencies associated with a manufacturing site inspection.

Data from 10 new randomized clinical trials support updated recommendations for various systemic therapy regimens in hepatocellular carcinoma.